A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials

References

• HaylenBTde RidderDFreemanRMAn International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunctionInt Urogynecol J201021152619937315
   PubMed Web of Science ®Google Scholar
• IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol20065061306131417049716
   PubMed Web of Science ®Google Scholar
• AbramsPKelleherCJKerrLARogersRGOveractive bladder significantly affects quality of lifeAm J Manag Care20006Suppl 11S580S59011183901
   PubMed Web of Science ®Google Scholar
• TubaroADefining overactive bladder: epidemiology and burden of diseaseUrology2004646 Suppl 12615621220
   PubMed Web of Science ®Google Scholar
• MilsomIAbramsPCardozoLRobertsRGThüroffJWeinAJHow widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence studyBJU Int200187976076611412210
   PubMed Web of Science ®Google Scholar
• HuTWWagnerTHBentkoverJDEstimated economic costs of overactive bladder in the United StatesUrology20036161123112812809878
   PubMed Web of Science ®Google Scholar
• ReevesPIrwinDKelleherCThe current and future burden and cost of overactive bladder in five European countriesEur Urol20065051050105716753252
   PubMed Web of Science ®Google Scholar
• HerbisonPHay-SmithJEllisGMooreKEffectiveness of anticholinergic drugs compared to placebo in the treatment of overactive bladder: systematic reviewBMJ2003326739484184712702614
   PubMed Web of Science ®Google Scholar
• ChappleCKhullarVGabrielZDooleyJAThe effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysisEur Urol200548152615885877
   PubMed Web of Science ®Google Scholar
• ChappleCRKhullarVGabrielZMustonDBitounCEWeinsteinDThe effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysisEur Urol200854354356218599186
   PubMed Web of Science ®Google Scholar
• ChappleCSteersWNortonPA pooled analysis of three Phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderBJU Int2005957993100115839920
   PubMed Web of Science ®Google Scholar
• ChappleCRSolifenacin provides effective antimuscarinic therapy for the complete management of overactive bladderExpert Opin Pharmacother20067172421243417109616
   PubMed Web of Science ®Google Scholar
• KhullarVRovnerESDmochowskiRNittiVWangJGuanZFesoterodine dose response in subjects with overactive bladder syndromeUrology200871583984318342923
   PubMed Web of Science ®Google Scholar
• SteersWCorcosJFooteJKralidisGAn investigation of dose titration with darifenacin, an M3-selective receptor antagonistBJU Int200595458058615705084
   PubMed Web of Science ®Google Scholar
• DmochowskiRRLarson-PetersAAronsteinWSSeifuYEfficacy of darifenacin in patients with varying baseline symptom severityUro Today Int J20092310.3834/uij.1944-5784.2009.06.16
   Google Scholar
• NapierCGuptaPDarifenacin is selective for the human recombinant M3 receptor subtypeInternational Continence Society [web page on the internet]Abstract 44582002 Available from http://www.icsoffice.org/Abstracts/AbstractsSearch.aspx?EventID=40
   Google Scholar
• OhtakeASaitohCYuyamaHPharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agentsBiol Pharm Bull2007301545817202659
   PubMed Web of Science ®Google Scholar
• AnderssonKEPotential benefits of muscarinic M3 receptor selectivityEur Urol2002Suppl 12328
   Web of Science ®Google Scholar
• AbramsPAnderssonKEBuccafuscoJJMuscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBr J Pharmacol2006148556557816751797
   PubMed Web of Science ®Google Scholar
• AbramsPWeinAThe Overactive Bladder: A Widespread but Treatable ConditionStockholm, SwedenErik Sparre Medical AB1998
   Google Scholar
• BravermanASLuthinGRRuggieriMRM2 muscarinic receptor contributes to contraction of the denervated rat urinary bladderAm J Physiol19982755 Pt 2R1654R16609791087
   PubMedGoogle Scholar
• GómezAMartosFBellidoIMuscarinic receptor subtypes in human and rat colon smooth muscleBiochem Pharmacol19924311241324191610405
   PubMed Web of Science ®Google Scholar
• KerrPMHillierKWallisRMGarlandCJCharacterization of muscarinic receptors mediating contractions of circular and longitudinal muscle of human isolated colonBr J Pharmacol19951158151815248564213
   PubMed Web of Science ®Google Scholar
• ChibaTBharuchaAEThomfordeGMKostLJPhillipsSFModel of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and a nitric oxide synthase inhibitorNeurogastroenterol Motil200214553554112358682
   PubMed Web of Science ®Google Scholar
• LiMJohnsonCPAdamsMBSarnaSKCholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colonAm J Physiol Gastrointest Liver Physiol20022833G544G55212181166
   PubMed Web of Science ®Google Scholar
• MatsuiMMotomuraDFujikawaTMice lacking M3 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viableJ Neurosci20022224106271063212486155
   PubMed Web of Science ®Google Scholar
• MatsuiMMotomuraDKarasawaHMultiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtypeProc Natl Acad Sci U S A200097179579958410944224
   PubMed Web of Science ®Google Scholar
• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
   PubMed Web of Science ®Google Scholar
• ChoungRSLockeGRIIISchleckGRZinsmeisterARTalleyNJCumulative incidence of chronic constipation: a population-based study 1988–2003Aliment Pharmacol Ther20072611–121521152817919271
   PubMed Web of Science ®Google Scholar
• ArmstrongRBDmochowskiRRSandPKMacdiarmidSSafety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two Phase 4 controlled clinical trialsInt Urol Nephrol20073941069107717333521
   PubMed Web of Science ®Google Scholar
• ElinoffVBavendamTGlasserDBCarlssonMEylandNRobertsRSymptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trialInt J Clin Pract200660674575116805763
   PubMed Web of Science ®Google Scholar
• ChappleCRCardozoLSteersWDGovierFESolifenacin significantly improves all symptoms of overactive bladder syndromeInt J Clin Pract200660895996616893438
   PubMed Web of Science ®Google Scholar
• Van KerrebroeckPKrederKJonasUZinnerNWeinATolterodine Study GroupTolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladderUrology200157341442111248608
   PubMed Web of Science ®Google Scholar
• MeekPDEvangSDTadrousMRoux-LirangeDTrillerDMGumustopBOveractive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trialsDig Dis Sci201156171820596778
   PubMed Web of Science ®Google Scholar
• DmochowskiRRNittiVStaskinDLuberKAppellRDavilaGWTransdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trialsWorld J Urol200523426327016151816
   PubMed Web of Science ®Google Scholar
• AbramsPSwiftSSolifenacin is effective for the treatment of OAB dry patients: a pooled analysisEur Urol200548348348716005564
   PubMed Web of Science ®Google Scholar
• ChappleCRRechbergerTAl-ShukriSRandomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU Int200493330331014764127
   PubMed Web of Science ®Google Scholar
• StaskinDSandPZinnerNDmochowskiRTrospium Study GroupOnce daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter Phase III trialJ Urol20071783 Pt 197898317632131
   PubMed Web of Science ®Google Scholar
• FooteJElhilaliMDarifenacin Study GroupBritish Geriatrics SocietyA multicenter, randomized, double-blind study of darifenacin versus tolterodine in the treatment of overactive bladder (OAB)Communications to the Autumn Meeting of the British Geriatrics Society: Programme of AbstractsPoster presented at the British Geriatrics Society Annual MeetingHarrogate, UKOctober 6–8, 2004 Poster 56. Available from: http://www.bgs.org.uk/PDF%20Downloads/Abstracts%20Autumn2004.pdfAccessed January 20, 2012.
   Google Scholar
• HillSKhullarVWyndaeleJJLheritierKDarifenacin Study GroupDose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose studyInt Urogynecol J Pelvic Floor Dysfunct200617323924715999217
   PubMed Web of Science ®Google Scholar
• HaabFStewartLDwyerPDarifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladderEur Urol200445442042915041104
   PubMed Web of Science ®Google Scholar
• HaabFCorcosJSiamiPLong-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension studyBJU Int20069851025103216879437
   PubMed Web of Science ®Google Scholar
• ZinnerNKobashiKCEbingerUDarifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapyInt J Clin Pract200862111664167418811599
   PubMed Web of Science ®Google Scholar
• ChancellorMBKianifardFBeamerEA comparison of the efficacy of darifenacin alone vs darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladderInt J Clin Pract200862460661318324952
   PubMed Web of Science ®Google Scholar
• ZinnerNSussetJGittelmanMArguinzonizMRekedaLHaabFEfficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OABInt J Clin Pract200660111912616409440
   PubMed Web of Science ®Google Scholar
• ChappleCDuBeauCEbingerURekedaLViegasADarifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trialCurr Med Res Opin200723102347235817706004
   PubMed Web of Science ®Google Scholar
• ChowS-CLiuJ-PChapter 13: Safety assessmentDesign and Analysis of Clinical Trials: Concepts and Methodologies2nd edHoboken, New Jersey, USJohn Wiley & Sons Inc2004
   Google Scholar
• FooteJGlavindKKralidisGWyndaeleJJTreatment of overactive bladder in the older patient: pooled analysis of three Phase III studies of darifenacin, an M3 selective receptor antagonistEur Urol200548347147715990219
   PubMed Web of Science ®Google Scholar
• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
   PubMed Web of Science ®Google Scholar